Relationships Between Advocacy Groups and Pharma
Applied Clinical Trials
Industry Standard Research
In a new report titled "Advocacy Groups: Enhancing Relationships and Patient Recruitment," Industry Standard Research interviewed 10 prominent patient advocacy groups to profile their involvement in clinical trials. All advocacy groups recognize clinical trials as a critical component of advancing knowledge. However, the degree of focus on educating patients about clinical trials and promoting participation in trials varies widely among organizations.
The organizations with a higher focus on clinical trials are the most involved in the clinical trial design process, frequently emphasizing the importance of patient relationships with industry, educating patients about trials, and partnering with pharma on trial-related endeavors.
Figure 1. Spectrum of clinical trial focus among advocacy groups.
Groups with a lower focus on clinical trials are not involved with the design of industry trials and do not have established processes to reach out to patients regarding trial education (general or related to specific trials). This is not to say that organizations not at the "high" end of the spectrum do not care about clinical trials. They do. They just have barriers to implementing a process encouraging patients to join industry's clinical trials that they have either been unable to or unwilling to cross.
—Industry Standard Research, www.ISRreports.com.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
